Replies to post #188233 on Biotech Values

[pollyvonwog]

In that $35 PT, Barclays gives ABBV peak rev of $2.5b on v-pak. In the same report they say they now expect ex-US sales to account for 70% of global HCV sales up from their previous estimate of 45%. Something doesn't quite add up when you put those two #s together.